Understanding — How Cannabinoids Work
Why Non-Intoxicating Cannabinoids Are Hard to Perceive: Interoception, Expectation, and Pharmacological Variability
Three documented reasons why CBD and CBG effects register as "nothing happened" even when something is — and one reason why the honest answer sometimes really is nothing happened.
The most common outcome after a first encounter with a CBD or CBG preparation is a report of no perceptible effect. This is documented in consumer research, consistent across product categories, and widely used as evidence that the compounds don't work. It is also significantly misunderstood.
Three distinct mechanisms produce the "felt nothing" outcome. Only one of them is evidence that the compound produced no effect. Understanding which mechanism is operating in a given case requires distinguishing between a perception problem, an expectation problem, and a genuine pharmacological non-response — three different situations that look identical from the outside.
Reason One — Interoceptive Variability
Interoception is the ability to perceive the internal state of the body — heartbeat, breathing, digestive activity, subtle changes in muscular tension, the quality of alertness or fatigue. It varies substantially between individuals. Some people have high interoceptive accuracy — they notice small physiological changes readily. Others have low interoceptive accuracy — they can have measurable physiological changes occurring and not register them consciously at all.
This is not a personality trait or a failure of attention. It is a documented individual difference in how the brain processes signals from the body, related to the function of the insular cortex and to prior learning about what internal signals to attend to. People with lower interoceptive awareness are measurably worse at tasks like counting their own heartbeat without taking their pulse. They are also measurably worse at detecting subtle drug effects — not because the drug isn't doing anything, but because the internal changes it produces are below the threshold of conscious detection for that individual.
Non-intoxicating cannabinoids produce effects that are, by their nature, subtle — a gradual shift in stress reactivity, a modest improvement in sleep architecture over days, a slight reduction in the speed and intensity of the cortisol response to a stressor. These are small signals in the body's ongoing noise. A person with high interoceptive sensitivity may notice them. A person with lower interoceptive sensitivity may not — even if the physiological changes are occurring.
The implication is important: the "felt nothing" report does not distinguish between no effect and an effect that fell below the perception threshold for that individual. These are different situations with different implications, but they are indistinguishable from subjective report alone.
Reason Two — Expectation Mismatch
Placebo research has extensively documented that expectation shapes perceived drug effect — expecting a compound to produce an effect increases the probability of perceiving one. Less studied, but equally real, is the inverse: expecting the wrong kind of effect can suppress recognition of the right one.
People approach cannabinoid preparations with prior templates — mostly derived from THC, alcohol, pharmaceutical sedatives, or strong analgesics. These compounds produce unmistakable signals with a recognisable character: a head change, euphoria, sedation, numbness, a clear alteration in the quality of consciousness. They announce their arrival. The scanner looking for these signals when using CBD or CBG is running the wrong search.
Non-intoxicating cannabinoids do not produce a head change. There is no moment of arrival to detect. Their effects accumulate over days and weeks — a gradual restoration of regulatory capacity in systems that had been chronically depleted. A person scanning for the wrong signal will reliably report "nothing happened" even if the compound is producing effects, because the effects don't match the expected pattern and therefore don't register as evidence of activity.
This is not purely a placebo phenomenon — it is an expectation mismatch phenomenon, and the distinction matters. The problem is not that expectation is failing to generate a fictional effect. The problem is that expectation is suppressing recognition of a real one by directing attention toward a signal that won't appear.
The SSRI Comparison
A related pattern appears in people who have come to associate relief with a particular quality of effect — most notably emotional flattening or numbness, which is how some people experience the benefit of SSRIs. A compound that produces a subtler, warmer, less flat quality of change — more "the noise got quieter" than "the volume was turned off" — may register as unsatisfying or even as "nothing" to someone calibrated to expect the flatter signal. This is not a value judgment about either type of effect. It is a description of how prior pharmacological experience shapes the perception template that subsequent compounds are evaluated against.
Reason Three — Genuine Pharmacological Variability
The first two reasons involve perception of a real effect. The third is distinct: genuine pharmacological non-response due to variability in absorption, metabolism, or receptor sensitivity. In this case, "nothing happened" is accurate — because at the dose and route used, insufficient compound reached the relevant tissue to produce a detectable effect.
Oral bioavailability of cannabinoids is highly variable. The gut absorbs cannabinoids more efficiently in the presence of dietary fat — taking an oral preparation without food can reduce absorption substantially compared to taking it after a fat-containing meal. Sublingual administration bypasses first-pass metabolism in the liver and produces more consistent absorption than swallowed preparations. These are not small differences — research on oral CBD bioavailability documents roughly 6% on an empty stomach, compared to substantially higher in a lipid-rich context.
Metabolic rate also varies. Cytochrome P450 enzyme activity — the liver enzyme system that processes cannabinoids — differs between individuals based on genetics. Fast metabolisers clear cannabinoids more quickly, reducing effective exposure. Some individuals are also taking medications that induce or inhibit these enzymes, which further alters the cannabinoid exposure they receive from any given dose.
Topical preparations introduce a different variable: penetration. Topical CBD acts locally in skin tissue and does not meaningfully enter systemic circulation. A person using a topical preparation hoping for systemic stress or sleep effects is not receiving a subtherapeutic dose of something that should work systemically — they are using a route that is mechanistically incapable of producing those effects.
These pharmacological variables explain genuine non-response in cases where the perception and expectation factors above are not operative. They are also addressable — by adjusting route, adjusting dose, adjusting timing relative to food — in ways that expectation mismatch and interoceptive variability require different approaches to address.
Why This Matters for an Honest Assessment
The three reasons above produce identical subjective reports — "I felt nothing" — but they represent fundamentally different situations. Interoceptive variability suggests measuring functional outcomes over time rather than acute felt effects. Expectation mismatch suggests recalibrating what signals to scan for. Genuine pharmacological non-response suggests adjusting route, dose, or timing before drawing conclusions.
None of these distinctions are in the interest of an industry that benefits from confident claims of effect regardless of mechanism. They are in the interest of the person trying to make an accurate assessment of whether a preparation is doing anything for them. That is the only assessment that actually matters.
References
- Garfinkel, S.N., & Critchley, H.D. (2013). Interoception, emotion and brain: New insights link internal physiology to social behaviour. Social Cognitive and Affective Neuroscience, 8(3), 231–234.
- Mehling, W.E., et al. (2018). If it all comes down to bodily awareness, how do we know? Assessing bodily awareness. PLOS ONE, 13(7), e0200460.
- Wager, T.D., & Atlas, L.Y. (2015). The neuroscience of placebo effects: Connecting context, learning and health. Nature Reviews Neuroscience, 16(7), 403–418.
- Zgair, A., et al. (2016). Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American Journal of Translational Research, 8(8), 3448–3459.
- Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics, 42(4), 327–360.
- Millar, S.A., et al. (2019). A systematic review on the pharmacokinetics of cannabidiol in humans. Frontiers in Pharmacology, 10, 1365.
- Huestis, M.A. (2007). Human cannabinoid pharmacokinetics. Chemistry & Biodiversity, 4(8), 1770–1804.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.